Viruses are the ultimate parasites as they derive nutrition from the host cell and also hijack and direct its metabolic machinery to synthesize new virus particles. Viruses can live and replicate only inside host body. Anti-viral drugs are specifically used to treat viral infections and act mostly by inhibiting their target viruses. The growth of antiviral drugs market is driven by factors such as rise in healthcare expenditure, growing research and development investment, emergence of virus life-threatening diseases like bird flu, strong development pipeline and increasing incidence rates of viral infections particularly HIV. WHO estimates 36.7 million people are suffering from HIV/AIDS worldwide with 1.1 million deaths of AIDS-related illnesses in 2015.
Taking all these factors the market for anti-viral drugs is expected to reach $62.67 billion by the end of the forecast period growing at a CAGR of 6.9%.
Key Players for Global Anti-Viral Drugs Market:
Some of the key players in this market are: Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Abbott Laboratories, Novartis International AG, Astra Zeneca AB, Cipla Inc.
Market Segments:
Global Anti-viral drugs market has been segmented on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others.
Request Customization
Get a Sample
Get a Sample
Request Customization